Autolus Therapeutics (AUTL) Gains from Investment Securities (2022 - 2025)

Autolus Therapeutics' Gains from Investment Securities history spans 4 years, with the latest figure at $429000.0 for Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 83.59% year-over-year to $429000.0; the TTM value through Dec 2025 reached $2.0 million, down 17.69%, while the annual FY2025 figure was $2.0 million, 17.69% down from the prior year.
  • Gains from Investment Securities reached $429000.0 in Q4 2025 per AUTL's latest filing, down from $501000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $2.6 million in Q4 2024 to a low of -$3.8 million in Q3 2023.
  • Average Gains from Investment Securities over 4 years is $51600.0, with a median of $9000.0 recorded in 2023.
  • Peak YoY movement for Gains from Investment Securities: skyrocketed 12347.62% in 2024, then plummeted 83.59% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at -$52000.0 in 2022, then surged by 140.38% to $21000.0 in 2023, then surged by 12347.62% to $2.6 million in 2024, then tumbled by 83.59% to $429000.0 in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Gains from Investment Securities are $429000.0 (Q4 2025), $501000.0 (Q3 2025), and $1.0 million (Q2 2025).